Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma

HIGHLIGHTS

• What: Due to the absence of identified therapeutic targets and limited treatment options for mucosal melanoma, numerous researchers, including the own research team, have conducted a series of translational research experiments focusing on this highly malignant subtype of melanoma . In the population-based PDX trial with 24 MM PDX models (14 cases with CDK4 amplification and 10 cases without CDK4 amplification), 37.5% of the models showed robust and sustained responses to palbociclib, with significant tumor growth inhibition observed in models with CDK4 amplification (8/14, 57%). This study was a single arm phase II trial and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.